BRL Medicine
Company Type: Therapeutic development
Main focus: Developing breakthrough curative treatments for various human diseases through gene editing
Company stage: Clinical
Diseases: Cancer, autoimmune diseases, and haemoglobinopathies
Genome-editing tool: CRISPR-Cas9
Funding stage: Series B
Location: Minhang District, Shanghai, China
Website: https://www.brlmed.com/en/index.html
Pipeline: https://www.brlmed.com/en/index.html
Partners:
BRL Medicine is a biotechnology company specialising in gene- and cell therapies. The company focuses on developing innovative treatments for genetic diseases, cancer, and immune disorders using advanced gene-editing and gene-modified cell technologies. BRL Medicine’s gene-editing technology innovation platform (CRISTARS®) is dedicated to developing gene-editing tools. The company’s pipeline features several pre-clinical and clinical trials involving both gene therapies and genetically-engineered cell therapies.